Neuroprotective and antioxidant effects of docosahexaenoic acid (DHA) in an experimental model of multiple sclerosis

J Nutr Biochem. 2024 Feb:124:109497. doi: 10.1016/j.jnutbio.2023.109497. Epub 2023 Oct 23.

Abstract

Multiple sclerosis (MS) is a chronic demyelinating disease, whose etiology is not yet fully understood, although there are several factors that can increase the chances of suffering from it. These factors include nutrition, which may be involved in the pathogenesis of the disease. In relation to nutrition, docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid (n-3 PUFA), has emerged as an important player in the regulation of neuroinflammation, being considered a pleiotropic molecule. This study aimed to evaluate the effect of DHA supplementation on clinical state and oxidative stress produced by experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Twenty-five Dark Agouti rats which were used divided into Control Group, Control+Vehicle Group, Control+DHA Group, EAE Group, and EAE+DHA Group. DHA was administered for 51 days by intraperitoneal (i.p.) injection at a dose of 40 mg/kg, once a day, 5 days a week. DHA supplementation produced a decrease in oxidative stress, as well as an improvement in the clinical score of the disease. DHA could exert a beneficial effect on the clinic of MS, through the activation of the antioxidant factor Nrf2.

Keywords: DHA; Experimental Autoimmune Encephalomyelitis; Glutathione Redox System; Multiple Sclerosis; Oxidative Stress.

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Docosahexaenoic Acids / pharmacology
  • Docosahexaenoic Acids / therapeutic use
  • Encephalomyelitis, Autoimmune, Experimental*
  • Fatty Acids, Omega-3* / pharmacology
  • Fatty Acids, Omega-3* / therapeutic use
  • Models, Theoretical
  • Multiple Sclerosis* / drug therapy
  • Rats

Substances

  • Antioxidants
  • Docosahexaenoic Acids
  • Fatty Acids, Omega-3